The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2023 | MDS 2023 highlights: classification and risk stratification systems & progression from CH to MDS
Norbert Vey, MD, PhD, Paoli-Calmettes Institute, Marseille, France, shares some of his highlights from the MDS 2023 meeting, commenting on presentations designed to help implement the new risk stratification and classification systems for myelodysplastic syndromes (MDS) in clinical practice, as well as advances in our understanding of the progression of clonal hematopoiesis (CH) to MDS. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
